Transcription factor regulatory protein

Abstract

The invention provides a mammalian nucleic acid sequence and fragments thereof. It also provides for the use of these nucleic acid sequences in a model system for the characterization, diagnosis, evaluation, treatment, or prevention of conditions, diseases and disorders associated with expression of the mammalian nucleic acid sequence. The invention additionally provides expression vectors and host cells for the production of the protein encoded by the mammalian nucleic acid sequence.

What is claimed is:  
     
         1 . A purified protein comprising the amino acid sequence of SEQ ID NO: 2.  
     
     
         2 . A method for using a protein to identify an antibody that specifically binds the protein having the amino acid sequence of SEQ ID NO: 1 comprising: 
 a) contacting a plurality of antibodies with the protein of  claim 1  under conditions to allow specific binding, and    b) detecting specific binding between an antibody and the protein, thereby identifying an antibody that specifically binds the protein.    
     
     
         3 . An antibody identified by the method of  claim 2 .  
     
     
         4 . The method of  claim 2 , wherein the plurality of antibodies are selected from a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a recombinant antibody, a bispecific antibody, a multispecific antibody, a humanized antibody, a single chain antibody, a Fab fragment, an F(ab′) 2  fragment, an Fv fragment; and an antibody-peptide fusion protein.  
     
     
         5 . A method of using a protein to prepare and purify a polyclonal antibody comprising: 
 a) immunizing a animal with a protein of  claim 1  under conditions to elicit an antibody response;    b) isolating animal antibodies;    c) attaching the protein to a substrate;    d) contacting the substrate with isolated antibodies under conditions to allow specific binding to the protein;    e) dissociating the antibodies from the protein, thereby obtaining purified polyclonal antibodies.    
     
     
         6 . A method of using a protein to prepare a monoclonal antibody comprising: 
 a) immunizing a animal with a protein of  claim 1  under conditions to elicit an antibody response;    b) isolating antibody-producing cells from the animal;    c) fusing the antibody-producing cells with immortalized cells in culture to form monoclonal antibody producing hybridoma cells;    d) culturing the hybridoma cells; and    e) isolating from culture monoclonal antibody that specifically binds the protein.    
     
     
         7 . A method for using an antibody to diagnose a condition or disease associated with expression of a protein, the method comprising: 
 a) combining the antibody of  claim 3  with a sample, thereby forming antibody:protein complexes; and    b) comparing complex formation with a standard, wherein the comparison indicates expression of the protein in the sample.    
     
     
         8 . A method for testing a molecule or compound for effectiveness as an agonist comprising: 
 a) exposing a sample comprising the protein of  claim 1  to the molecule or compound, and    b) detecting agonist activity in the sample.    
     
     
         9 . A method for testing a molecule or compound for effectiveness as an antagonist, the method comprising: 
 a) exposing a sample comprising the protein of  claim 1  to a molecule or compound, and    b) detecting antagonist activity in the sample.    
     
     
         10 . An isolated antibody that specifically binds a protein having the amino acid sequence of SEQ ID NO:2.  
     
     
         11 . A polyclonal antibody produced by the method of  claim 5 .  
     
     
         12 . A monoclonal antibody produced by the method of  claim 6 .  
     
     
         13 . A method for using an antibody to detect expression of a protein in a sample, the method comprising: 
 a) combining the antibody of  claim 10  with a sample under conditions which allow the formation of antibody:protein complexes; and    b) detecting complex formation, wherein complex formation indicates expression of the protein in the sample.    
     
     
         14 . A method for using an antibody to immunopurify a protein comprising: 
 a) attaching the antibody of  claim 10  to a substrate,    b) exposing the antibody to a sample containing protein under conditions to allow antibody:protein complexes to form,    c) dissociating the protein from the complex, and    d) collecting the purified protein.    
     
     
         15 . A composition comprising an antibody of  claim 10  and a labeling moiety.  
     
     
         16 . A kit comprising the composition of  claim 15 .  
     
     
         17 . An array element comprising the antibody of  claim 10 .  
     
     
         18 . A substrate upon which the antibody of  claim 10  is immobilized.  
     
     
         19 . A method for using a composition to assess efficacy of a molecule or compound, the method comprising: 
 a) treating a sample containing protein with a molecule or compound;    b) contacting the protein in the sample with the composition of  claim 15  under conditions for complex formation;    c) determining the amount of complex formation; and    d) comparing the amount of complex formation in the treated sample with the amount of complex formation in an untreated sample, wherein a difference in complex formation indicates efficacy of the molecule or compound.    
     
     
         20 . A method for using a composition to assess toxicity of a molecule or compound, the method comprising: 
 a) treating a sample containing protein with a molecule or compound;    b) contacting the protein in the sample with the composition of  claim 15  under conditions for complex formation;    c) determining the amount of complex formation; and    d) comparing the amount of complex formation in the treated sample with the amount of complex formation in an untreated sample, wherein a difference in complex formation indicates toxicity of the molecule or compound.